Results for tag: "Juvenile Idiopathic Arthritis"

Juvenile Idiopathic Arthritis (JIA) is a type of autoimmune disorder that affects children and adolescents. It is the most common type of arthritis in children and is classified as an allergy and immunology disorder. JIA is characterized by inflammation of the joints, which can cause pain, stiffness, and swelling. It can also affect other organs, such as the eyes, skin, and lungs. Treatment for JIA typically involves medications, physical therapy, and lifestyle modifications. JIA is a growing market within the allergy and immunology space, with a focus on developing treatments that can reduce inflammation and improve quality of life for those affected. Companies in this market are researching and developing new treatments, such as biologics, to target the underlying cause of the disease. Companies in the Juvenile Idiopathic Arthritis market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer, and UCB. Show Less Read more